Why the study?
Does ultrapure dialysate prevent the rise of Lipoprotein(a) levels in patients on long-term hemodialysis compared to conventional dialysate?
Does ultrapure dialysate prevent the rise of Lipoprotein(a) levels in patients on long-term hemodialysis compared to conventional dialysate?
Ultrapure dialysate prevents the progressive rise of Lipoprotein(a) levels seen with conventional dialysate in patients on long-term hemodialysis, potentially mitigating cardiovascular risk.
Answers are grounded in this paper and cite their sources.
Ultrapure dialysate may lower cardiovascular risk in long-term hemodialysis; extends RCT evidence supporting its broader adoption over conventional dialysate.
PURPOSE: In patients on long-term hemodialysis, high lipoprotein(a) [Lp(a)] levels are difficult to lower with medications, although they remain a risk factor for cardiovascular disease. We investigated whether ultrapure dialysate (UPD) could lower Lp(a). METHODS: We randomly assigned patients stabilized on long-term dialysis to either a low-flux synthetic polysulphone membrane (the UPD group; n=14) or to a conventional dialysate (the CD group; n=13). Blood samples were collected 1 week before dialysis and 1 week, 1 month, 6 months and 12 months after dialysis; Lp(a) was measured by the immunoturbidimetry method. Hemoglobin, interleukin-6, hypersensitive C-reactive protein, beta(2) microglobulin and albumin were also measured. The erythropoietin dosage, Kt/V, and normalized protein catabolic rate were recorded monthly. RESULTS: At 12 months, mean (SD) serum levels of Lp(a) in the CD patients increased from 143.46 (125.11) to 283.89 (145.81) mg/L (p<0.01), whereas levels in the UPD group remained unchanged: 131.38 (201.45) to 120.90 (122.11) mg/L. Endotoxin levels in the 10 CD patients who completed the study ranged from 0.116 to 0.349 EU/mL and were undetectable in the 11 UPD patients who completed the study. The cultures were less than 200 CFU/mL in CD patients and negative all the time for all UPD patients. Changes in Lp(a) from baseline values were lower in the UPD group than in the CD group (p<0.05). However, changes in other variables did not differ between groups. CONCLUSIONS: Ultrapure dialysate can prevent the rise of Lp(a), potentially decreasing the risk of cardiovascular disease in hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: